×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
AIM ImmunoTech reports progress in pancreatic cancer drug trial
Clinical Trials Arena
AIM ImmunoTech has reported significant progress in its Phase Ib/II trial of Ampligen and Imfinzi for late-stage pancreatic cancer.
4 days ago
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi ...
Yahoo Finance Canada
Next safety cohort to begin escalated dosing soonOCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)...
5 days ago
Kellner v. AIM ImmunoTech, Inc. provides key guidance on advance notice bylaw provisions
The Harvard Law School Forum on Corporate Governance
On December 28, 2023, Vice Chancellor Will of the Delaware Court of Chancery rendered an important decision in Kellner v. AIM ImmunoTech...
3 months ago
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GlobeNewswire
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next...
1 week ago
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Yahoo Finance
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next...
2 weeks ago
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GlobeNewswire
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next...
2 weeks ago
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host ...
Yahoo Finance
OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that...
1 month ago
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
Yahoo Finance
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen's potential...
2 months ago
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ...
GlobeNewswire
OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD,...
3 weeks ago
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Yahoo Finance
Year marked by growing body of promising data demonstrating Ampligen's potential to address multiple high-value indications Company to host...
1 month ago